miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.

miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.
复制标题

miR-181d 和 c-myc 介导的 CRY2 和 FBXL3 抑制可重新编程结直肠癌的代谢。

DOI:
10.1038/cddis.2017.300
复制
发表时间:
2017-07-27
影响因子:
9
通讯作者:
Hong X
Hong X
中科院分区:
生物学1区
文献类型:
--
作者:
Guo X;Zhu Y;Hong X;Zhang M;Qiu X;Wang Z;Qi Z;Hong X

文献摘要

参考文献

被引文献

相似文献

结直肠癌(CRC)是肿瘤相关死亡的第二大原因。microRNA(miRNAs)在CRC进展中起关键作用。在这里,我们描述了miR-181 d对CRC细胞代谢的影响及其潜在的分子机制。我们的数据坚定地表明,敲低miR-181 d通过损害糖酵解抑制CRC细胞增殖、迁移和侵袭。miR-181 d通过直接靶向FBXL 3和FBXL 2的3′-UTR来稳定c-myc,从而增加葡萄糖消耗和乳酸产生。通过siRNA或小分子抑制剂抑制c-myc可消除miR-181 d对CRC细胞生长和转移的致癌作用。此外,发现c-myc/HDAC 3转录抑制因子复合物共定位于CRP 2和FBXL 3启动子上,表观遗传地抑制它们的转录,并最终诱导它们在CRC细胞中的下调。此外,miR-181 d的表达可以通过c-myc信号传导的激活直接诱导。总之,我们的数据表明miR-181 d通过促进糖酵解在CRC中发挥致癌作用,miR-181 d/BMP 2/FBXL 3/c-myc反馈环可能是CRC患者的治疗靶点。
Colorectal cancer (CRC) is the second major cause of tumor-related deaths. MicroRNAs (miRNAs) have pivotal roles in CRC progression. Here, we describe the effect of miR-181d on CRC cell metabolism and underlying molecular mechanism. Our data firmly demonstrated that knockdown of miR-181d suppressed CRC cell proliferation, migration, and invasion by impairing glycolysis. Mechanistically, miR-181d stabilized c-myc through directly targeting the 3′-UTRs of CRY2 and FBXL3, which subsequently increased the glucose consumption and the lactate production. Inhibition of c-myc via siRNA or small molecular inhibitor abolished the oncogenic effects of miR-181d on the growth and metastasis of CRC cells. Furthermore, c-myc/HDAC3 transcriptional suppressor complex was found to co-localize on the CRY2 and FBXL3 promoters, epigenetically inhibit their transcription, and finally induce their downregulation in CRC cells. In addition, miR-181d expression could be directly induced by an activation of c-myc signaling. Together, our data indicate an oncogenic role of miR-181d in CRC by promoting glycolysis, and miR-181d/CRY2/FBXL3/c-myc feedback loop might be a therapeutic target for patients with CRC.
DOI: 10.1158/0008-5472.can-14-3521
发表时间: 2015-08-15
期刊: Cancer research
影响因子: 11.2
作者:
Bräuer-Hartmann D;Hartmann JU;Wurm AA;Gerloff D;Katzerke C;Verga Falzacappa MV;Pelicci PG;Müller-Tidow C;Tenen DG;Niederwieser D;Behre G
通讯作者: Behre G
DOI: 10.5483/bmbrep.2015.48.4.007
发表时间: 2015-04
期刊: BMB reports
影响因子: 3.8
作者:
Hur K
通讯作者: Hur K
DOI: 10.1177/1534735409355292
发表时间: 2009-12-01
影响因子: 2.9
作者:
Wood, Patricia A.;Yang, Xiaoming;Hrushesky, William J. M.
通讯作者: Hrushesky, William J. M.
miR-592/WSB1/HIF-1 α轴抑制糖酵解代谢以减少肝细胞癌的生长
DOI: 10.18632/oncotarget.9135
发表时间: 2016-06-07
期刊: Oncotarget
影响因子: --
作者:
Jia YY;Zhao JY;Li BL;Gao K;Song Y;Liu MY;Yang XJ;Xue Y;Wen AD;Shi L
通讯作者: Shi L
DOI: 10.1073/pnas.0914433107
发表时间: 2010-02-02
影响因子: 11.1
作者:
Le, Anne;Cooper, Charles R.;Dang, Chi V.
通讯作者: Dang, Chi V.